Genovis ABOSTO:GENO +4.06%94 Median PS Value is kr34.84 as of Jul. 02, 2026, which is 100% below its 10-year median of 2.85. GuruFocus rates OSTO:GENO with a GF Score™ of 94/100 and a GF Value™ of kr28.56 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 277 Biotechnology companies, Genovis AB ranks better than 55.6% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Genovis AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr1.974. Genovis AB's 10-Year median PS Ratio is 17.6494. Therefore, the Median PS Value for today is kr34.84.
As of today (2026-07-02), Genovis AB's share price is kr20.50. Genovis AB's Median PS Value is kr34.84. Therefore, Genovis AB's Price to Median PS Value for today is 0.59.
The historical rank and industry rank for Genovis AB's Median PS Value or its related term are showing as below:
OSTO:GENO'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.52 Med: 2.85 Max: 6.74
Current: 0.59
During the past 13 years, the highest Price to Median PS Value of Genovis AB was 6.74. The lowest was 0.52. And the median was 2.85.
OSTO:GENO's Price-to-Median-PS-Value is ranked better than 55.6% of 277
companies
in the Biotechnology industry
Industry Median: 0.63
vs OSTO:GENO: 0.59
Genovis AB (OSTO:GENO) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Genovis AB's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
20.50
/
34.84
=
0.59
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genovis AB Median PS Value Related Terms
Genovis AB Median PS Value Historical Data
* Premium members only.
The historical data trend for Genovis AB's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:GENO vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, Genovis AB's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genovis AB Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genovis AB's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Genovis AB's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 17.6494.
Genovis AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.974.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genovis AB (OSTO:GENO) has a Median PS Value of kr34.84 as of Jul. 02, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Genovis AB and its competitors. This is 1122% above median its historical median of 2.85. Over the past decade, Genovis AB's Median PS Value has ranged from 0.52 to 6.74. According to the industry distribution chart, Genovis AB ranks #123 out of 277 companies in the Biotechnology industry, placing it in the top 44.4%.
Is Genovis AB's Median PS Value too high?
Genovis AB's current Median PS Value of kr34.84 is 1122% above median its 10-year median of 2.85. Over the past 10 years, this metric has ranged from a low of 0.52 to a high of 6.74. Based on the distribution chart, Genovis AB ranks #123 out of 277 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Genovis AB has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genovis AB's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genovis AB ranks #123 out of 277 companies for Median PS Value. This puts Genovis AB in the upper half of its industry. The industry median Median PS Value is 0.63. Historically, Genovis AB's own Median PS Value has ranged from 0.52 to 6.74 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Genovis AB and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genovis AB's current Median PS Value is kr34.84, which is 1122% above median its own 10-year median of 2.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovis AB stock overvalued right now?
Based on GuruFocus' analysis, Genovis AB (OSTO:GENO) is currently considered Modestly Undervalued. The stock's GF Value™ is kr28.56, compared to a current price of kr20.50 — trading 28.2% below its estimated fair value. The current Median PS Value is kr34.84, which is 1122% above median its 10-year median of 2.85. Genovis AB's overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Genovis AB (OSTO:GENO), the current Median PS Value is kr34.84 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genovis AB (OSTO:GENO) Overvalued in 2026?
Based on GuruFocus' analysis, Genovis AB stock appears to be undervalued.
The current stock price of kr20.50 is trading 28.2% below its estimated GF Value™ of kr28.56.
GuruFocus considers Genovis AB to be Modestly Undervalued.
Key valuation signals for OSTO:GENO:
Median PS Value: kr34.84 (1122% above median its 10-year median of 2.85)
GF Value™: kr28.56 vs. price of kr20.50 (28.2% below fair value)
No single metric tells the full story. See the OSTO:GENO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genovis AB offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Its enzyme products, known as SmartEnzymes, are used by scientists all over the world, and the product formats facilitate the development and quality control of biological drugs. Its products include Enzyme and Antibodies. Geographically, it operates in Sweden and Rest of the world.
94GF Score
Get the complete analysis for OSTO:GENO
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:GENO has been successfully added to your 
